Stability and solidification of thymol-loaded self-microemulsifying drug delivery system
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F24%3A00135800" target="_blank" >RIV/00216224:14160/24:00135800 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Stability and solidification of thymol-loaded self-microemulsifying drug delivery system
Original language description
Self-emulsifying drug delivery systems (SEDDS) have gained recognition as a crucial approach to enhancing the bioavailability of poorly water-soluble drugs. Thymol boasts a plethora of biological effects, such as anti-inflammatory, antioxidant, immunomodulatory, and analgesic properties. Thymol is a GRAS candidate for preventing and treating inflammatory bowel diseases. Given their limited bioavailability, thymol presents a promising candidate for inclusion in self-emulsifying systems. Nevertheless, liquid SEDDS pose challenges, including the potential irritation caused by a high surfactant content on the gastrointestinal mucosa, reduced formulation stability, and complexities in handling. Solid SEDDS, conversely, are solidified self-emulsifying formulations achieved by converting liquid SEDDS into self-emulsifying powders or particles. Neusilin® US2 was chosen as the solid carrier for thymol SMEDDS formulation. The optimized T-SMEDDS formulations underwent long-term stability tests, and six months stability was demonstrated. The optimal ratio of T-SMEDDS formulation with the solid carrier Neusilin® US2 was 2:1. In vitro dissolution characteristics was determined using biorelevant media FaSSIF. The release of more than 85% of thymol from the T-SMEEDS formulation within 15 minutes indicates a reasonable presumption for enhanced thymol bioavailability in the biosystem.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
<a href="/en/project/GA22-03187S" target="_blank" >GA22-03187S: Rational Design of Polysaccharide‐based Particulate Systems for the Delivery of Mucosal Therapeutics with Broad Spectrum of Biological Activities</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů